Viking Therapeutics, Inc.
http://www.vikingtherapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Viking Therapeutics, Inc.
Phase III Data In Suspected NASH Boost Madrigal’s Profile, But Bigger Data To Come
Resmetirom, Madrigal’s THRβ agonist, demonstrates safety and tolerability, and succeeds on secondary efficacy endpoints in a study serving as a precursor to the firm’s pivotal Phase III trial.
Terns Says Phase IIa Data Show Superior NASH Safety Profile In FXR Class
TERN-101 showed a superior safety and tolerability profile for lipid levels and pruritis compared to other FXR agonists in a mid-stage study. Terns is now looking to a NASH combo study with its THR beta agonist.
Terns Raises $87m More For NASH R&D, Including Lilly Equity Purchase
In its third venture funding round, Terns adds backing from Deerfield in addition to Lilly’s investment. It licensed three non-alcoholic steatohepatitis candidates from the big pharma in 2018.
Year Of NASH Upheaval Means Incremental Data At AASLD
With still no approved therapy for non-alcoholic steatohepatitis, Intercept, Madrigal, Inventiva and others used the liver meeting to build the cases for their NASH candidates.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals